Ginkgo Bioworks Holdings (DNABW) Non Operating Investment Income (2020 - 2026)
Ginkgo Bioworks Holdings (DNABW) reported Non Operating Investment Income of -$1.2 million for Q1 2026, up 67.13% on a YoY basis from -$726393.7 in Q1 2025, and up 92.49% quarter-over-quarter from -$16.2 million in Q4 2025.
Ginkgo Bioworks Holdings (DNABW) Non Operating Investment Income (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings has reported Non Operating Investment Income for 7 years, with the latest figure at -$1.2 million in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Investment Income rose 67.13% year-over-year to -$1.2 million; the trailing twelve-month figure through Mar 2026 stood at -$13.9 million (up 53.52% YoY), and the FY2025 full-year result was -$16.4 million, up 43.07% from the prior year.
- Non Operating Investment Income for Q1 2026 stood at -$1.2 million, up from -$16.2 million in the prior quarter.
- The five-year high for Non Operating Investment Income was $3.7 million in Q3 2025, with the low at -$38.7 million in Q2 2022.
- Historically, Non Operating Investment Income has averaged -$9.1 million across 5 years, with a median of -$6.4 million in 2023.
- Annual changes were most pronounced in 2023 — Non Operating Investment Income tumbled 1966.21% — and 2025, when it jumped 153.3%.
- Ginkgo Bioworks Holdings' Non Operating Investment Income stood at -$13.4 million in 2022, then climbed by 25.03% to -$10.0 million in 2023, then dropped by 25.3% to -$12.5 million in 2024, then retreated by 28.92% to -$16.2 million in 2025, then surged by 92.49% to -$1.2 million in 2026.
- The last three Non Operating Investment Income figures came in at -$1.2 million (Q1 2026), -$16.2 million (Q4 2025), and $3.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 235,807.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 230,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ginkgo Bioworks Holdings | - | - | 16.38 Mn | -1.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.21 Mn |
| Mar 31, 2026 | -1.21 Mn |
| Dec 31, 2025 | -16.17 Mn |
| Dec 31, 2025 | -16.17 Mn |
| Sep 30, 2025 | 3.68 Mn |
| Sep 30, 2025 | 3.68 Mn |
| Jun 30, 2025 | -229,000.00 |
| Jun 30, 2025 | -229,000.00 |
| Mar 31, 2025 | -3.69 Mn |
| Mar 31, 2025 | -3.69 Mn |
| Dec 31, 2024 | -12.55 Mn |
| Dec 31, 2024 | -12.55 Mn |
| Sep 30, 2024 | -6.91 Mn |
| Sep 30, 2024 | -6.91 Mn |
| Jun 30, 2024 | -6.83 Mn |
| Jun 30, 2024 | -6.83 Mn |
| Mar 31, 2024 | -2.54 Mn |
| Mar 31, 2024 | -2.54 Mn |
| Dec 31, 2023 | -10.01 Mn |
| Dec 31, 2023 | -10.01 Mn |